<DOC>
	<DOCNO>NCT00775294</DOCNO>
	<brief_summary>This study conduct look body handle drug maraviroc . It measure amount maraviroc blood , semen , saliva rectum men . The aim understand much drug ( take mouth ) reach oral , reproductive intestinal tract . It believe presence drug area may beneficial prevent AIDS virus ( HIV ) pass one person another . The study take sample blood , saliva , semen rectal mucosal tissue measure drug level . This study also collect information side effect .</brief_summary>
	<brief_title>Study Healthy Males Measure Maraviroc Blood , Saliva , Seminal Fluid , Rectal Tissue</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male subject age 18 49 year , inclusive , intact genital tract gastrointestinal tract . ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG individual &gt; 35yo clinical laboratory test ) . Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; /=50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject inform pertinent aspects trial . Willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subjects history gastrectomy , colostomy , ileostomy , procedure alter gastrointestinal tract . Subjects inflammatory bowel disease ( ulcerative colitis Crohn 's disease ) clearly define diagnosis irritable bowel syndrome . Subject unwilling refrain sexual activity include intercourse masturbation 72 hour prior study visit Day 1 discharge study . Subject unwilling refrain rectal insertion medical/recreation device product receptive anal intercourse , 72 hour study visit Day 1 7 day last biopsy unless instructed otherwise investigator . History febrile illness within 5 day prior first dose . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . A positive result HIV . Active hepatitis B infection define positive Hepatitis B surface antigen ( HbsAg ) OR positive Hepatitis B core antibody negative Hepatitis B surface antibody ( HBsAb ) . Active hepatitis C infection define antihepatitis C virus serology ( determine multiantigen EIA ) detectable HCV RNA . A positive test syphilis , gonorrhea , Chlamydia , HSV2 ( active lesion ) trichomonas screen . History regular alcohol consumption exceed 14 drink ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) spirit ) per week . Participation clinical study within 4 month precede first dose trial medication . Participation rectal biopsy study 12 month precede first dose trial medication . Use prescription nonprescription drug , vitamin dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose trial medication . Herbal supplement must discontinue 14 day prior first dose trial medication . As exception , acetaminophen may use dos &lt; /= 1 g/day Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . History sensitivity heparin heparininduced thrombocytopenia . Unwilling abstain alcohol use 24 hour prior first dose study medication followup visit . Unwilling abstain cigarette smoke completely inpatient pharmacokinetic visit unwilling limit smoke maximum 5 cigarette per day 24 hour prior start study study completion . Unwilling unable comply dietary restriction regard study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>